In response to the COVID-19 pandemic, many pharmaceutical companies around the world have been racing to produce an effective vaccine. Pfizer and their German partner BioNTech were the first to receive emergency authorization for their mRNA vaccine. Within weeks, Moderna (MRNA 0.43%) also received approval for its similar mRNA vaccine.
Both companies were able to gear up their manufacturing processes to capture the U.S. market while competitors like Johnson & Johnson, AstraZeneca, and Novavax (NVAX 3.27%) ran into regulatory and production issues which blunted their efforts.
Because of its successful development and manufacturing ramp up, as of Q1 Moderna had Advance Purchase Agreements (APAs) of $19.2 billion; and it expects to ship 800 million to 1 billion doses by the end of 2021.
Image source: Getty images.
To the victor go the spoils
Because Moderna doesn't have to split profits with a partner, it's likely to make more money from its vaccine sales than either Pfizer or BioNTech. Pfizer is also a much larger company, so it takes a lot more to move its price. As a result, Moderna has been the big winner in the stock market over the last year, with its stock price rising 377% in the last 52 weeks versus 235% for BioNTech and 17% for Pfizer.
The big question many investors are asking themselves, "Is it too late to buy Moderna?"
The next leg of the race
Despite the early successes, there are three things investors need to know before deciding if Moderna is a buy:
1. Competing for the global opportunity
The competitive landscape may change as the focus shifts from the U.S. to the rest of the world. Despite initial stumbles, Novavax may have some advantages in global distribution since it can be refrigerated at lower temperatures and is therefore easier to transport and store. The Novavax advantages could result in splitting the global market across more players, thereby reducing Moderna's opportunity.
2. Developing a combo COVID-19 and flu vaccine
Moderna, Novavax, and Pfizer-BioNTech are working on developing a combination vaccine to address COVID-19 and the flu in a single shot. A successful combo vaccine could change the competitive dynamics since both healthcare providers and patients may prefer a single annual shot. Novavax is thought to be somewhat ahead of the game since it has a flu vaccine in clinical trials already, but combo vaccine trials are not expected to be completed until 2025.
3. Pipeline of additional mRNA vaccines and medicines
The COVID-19 vaccine is a great proof point that mRNA vaccines actually work and might be effective in treating a variety of other viruses. Moderna has nine other vaccines in various stages of development, including the mRNA-1647 program targeting cytomegalovirus (CMV) which is expected to enter phase 3 trials this year. The hope is by vaccinating mothers you can prevent CMV in babies, which occurs in one out of every 200 births.
Beyond vaccines, Moderna is hoping to use mRNA to solve challenges in treating a variety of other conditions. As an example, Moderna and AstraZeneca have a 50/50 partnership for the AZD8601 program to develop a regenerative therapeutic for the heart. The program, currently in phase 2 trials, aims to rebuild blood vessels, improve blood flow, and partially restore heart function in patients with coronary artery disease. An estimated 9 million people die from this heart disease each year.
Keep an eye on these developments
Moderna is scheduled to report Q2 earnings on August 5. Smart investors will look for progress on global approvals and APAs, long-term progress on flu and combination vaccines, and continued development of the pipeline beyond COVID-19 vaccines.
Moderna had quite the year with a large run up in its stock price. It would be easy to build a case for Moderna being overvalued based on the COVID-19 vaccine alone. If Moderna can build on its progress with additional mRNA vaccines and medicines, there should be a long runway of future growth. For patient buy-and-hold investors, Moderna could be a long-term winner for your portfolio.
